8-K ·Filed Apr 1, 2026
earnings-rerun-backfill
Actionable Insight ▼ Bearish
Monitor cash burn rate and upcoming clinical trial readouts in 2026; the recent capital raise may not be sufficient given the increased R&D spend and lack of revenue generation.
Final — all horizons settled through T+60d
FBRX ▼ -14.24% at T+60d
SHORT call ✓ call won +14.24% · α vs SPY +27.62% · entry $24.86 → $21.32
T+1d
+2.90%
call -2.90% · α -2.82%
$25.58
settled 6mo ago
T+5d
+36.36%
call -36.36% · α -32.60%
$33.90
settled 6mo ago
T+20d
+12.75%
call -12.75% · α -3.03%
$28.03
settled 5mo ago
T+60d
-14.24%
call +14.24% · α +27.62%
$21.32
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates, with R&D expenses nearly tripling due to clinical trial advancement. This follows a recent $150M follow-on offering, raising concerns about capital efficiency.
Key Financial Metrics
EPS
$-4.71
est $-1.16 · -276.7%
Revenue
$0.00
est $0.00 · 0.0%
Rating
strong miss
Key Facts
- Net loss per share was $(4.71) for FY 2025, missing consensus of $-1.16
- R&D expenses increased to $58.2M from $21.2M in 2024 due to clinical trials
- Cash and cash equivalents decreased to $77.0M from $93.4M in Q3 2025
- Recent $150M follow-on offering completed just 12 days prior to earnings
Financial Impact
Net loss of $69.375M vs consensus expectations of $20.0M loss
epscashr&d_expenses
Risk Factors
- High cash burn rate may necessitate additional capital raises
- Clinical trial failures could further impact stock performance
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-135767 |
| Document: d63145d8k.htm | 0001193125-26-135767 |
| Document: 0001193125-26-135767-index-headers.html | 0001193125-26-135767 |
| Document: 0001193125-26-135767-index.html | 0001193125-26-135767 |
| Document: 0001193125-26-135767.txt | 0001193125-26-135767 |
| 8-K Data (Synthetic) | 0001193125-26-135767 |
12 reports for FBRX
50% Hit rate best @ T+60▲ +39.79%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Aug 27, 2026 5w ago | 25-NSE | $76.99 $76.99 | · 0.00% | ▼ −0.23% | — |
Jul 27, 2026 9w ago | 8-K | $76.50 $76.65 | ▲ +0.20% | ▼ −0.04% | — |
Jun 11, 2026 16w ago | EFFECT | $17.40 $17.56 | ▼ −0.92% | ▼ −0.38% | — |
Jun 6, 2026 16w ago | S-3/A | $15.67 $17.00 | ▼ −8.49% | ▼ −8.78% | — |
Jun 2, 2026 17w ago | S-3 | $17.00 $16.69 | ▲ +1.82% | ▲ +2.22% | — |
Jun 2, 2026 17w ago | 8-K | $17.00 $16.69 | ▼ −1.82% | ▼ −2.23% | — |
May 14, 2026 20w ago | 8-K | $23.11 $20.97 | ▼ −9.26% | ▼ −9.20% | — |
Apr 9, 2026 25w ago | 8-K | $33.90 $35.09 | ▲ +3.51% | ▲ +3.57% | — |
Showing 10 of 12
US Market Status
Market Closed — Opens Mon (65h 27m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access